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Osmotic brain edema or chronic treatment with desipramine alters brain water 
permeability.  In this study we investigated aquaporin 4 expression and distribution in 
these two conditions.  Brain edema development was induced by intraperitoneal water 
injection.  Blood serum osmolality decreased from 296 ± 1 mOsm to 278 ± 2 mOsm 
within 15 min.  Cerebral cortex water content increased from 79.8 ± 0.2 % to 81.3 ± 0.5% 
during 120 min of this hyposmotic exposure.  Aquaporin 4 immunostaining intensity at 
the astrocytic endfeet increased in water injected animals from 2.6 ± 0.04 intensity unites 
(IU) to 3.2 ± 0.21 IU, while total brain AQP4 expression remained unaltered.  Chronic 
treatment with desipramine showed no significant change in serum osmolality or cerebral 
cortex water content.  Similar to water injected animals, aquaporin 4 immunostaining 
intensity in chronic desipramine animals increased at the astrocytic endfeet (2.5 ± 0.04 IU 
to 3.0 ± 0.13) but total cortical AQP4 expression was again unaltered.  These experiments 
suggest that decreased brain water permeability caused by osmotic brain edema is not a 
result of decreased AQP4 expression or localization of astroglial endfeet.  However 
chronic treatment with desipramine increases AQP4 immunostaining at the astrocytic 
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The blood-brain barrier is relatively impermeable to many amino acids, peptides 
and ions. Nonpolar gases, transit this structure by simple diffusion, while essential polar 
and charged molecules must cross through via carrier mediated transport or channels.  
The selectivity of the blood-brain barrier results from a unique endothelial cell system 
that is connected through tight junctions and is free of any fenestrations.  The 
maintenance and regulation of the blood-brain barrier and its associated transporters 
occurs through perivascular neurons and glial cells which combine with the endothelial 
cell network to form the neurovascular unit.   
A group of transmembrane water channel proteins called aquaporins are involved 
in water transport in several organs.  Aquaporin 4 is found at the astrocytic endfeet 
surrounding cerebral capillaries. The localized polarity of aquaporin-4 to the astrocytic 
endfeet may be a result of several adjacent proteins including syntropin and dystrophin.  
The role of aquaporin 4 in water transport during pathological injuries has recently been 
examined by several authors.  In cellular brain edema caused by systemic hyponatremia 
aquaporin 4 has been shown to be detrimental to the survival of animals.  During edema 
caused by a disruption of the blood brain barrier however, aquaporin-4 plays a beneficial 
role in clearing excess interstitial fluid, thus increasing the chance of survival.   
Regulation of aquaporin 4 occurs largely at the c-terminus by the phosphorylation of 
several kinases (PKC, PKA, PKG, and CaMKII).  Several drugs, altering kinase activity 
have been used to attenuate brain edema.  
Development of osmotic edema and the use of tricyclic antidepressants have 
previously been shown to alter water permeability in the brain.  Various changes in 
aquaporin 4 localization have been reported during osmotic edema.  In addition, the role 
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of the noradrenergic system on aquaporin 4 in the brain has not yet been studied.  The 
purpose of this thesis is to determine if the alteration of cerebral water permeability 
caused by chronic use of antidepressants and induced osmotic brain edema is the result of 







































1. Blood-brain barrier and aquaporin 
Blood-brain barrier  
The blood-brain barrier (BBB) is a highly selective endothelial cell system that 
differs from that found in the rest of the body. The BBB is relatively impermeable to 
many amino acids, peptides, and ions. Some nonpolar gases such as oxygen and carbon 
dioxide can be transported freely across membrane while larger polar molecules such as 
glucose and amino acids require carrier mediated transport [1].  Any charged substances 
such as ions (sodium, potassium, chloride and bicarbonate) must cross the BBB by active 
transport [1, 2].  Endothelial cells that compose the barrier are free of fenestrations and 
are attached to each other by an extensive system of junctional complexes including tight 
junctions and adherens junctions [3, 4].  The tight junctions associated with BBB include 
three main integral proteins; claudins [5], occludens [6] and junctional adhesion 
molecules [7].  The regulation and possibly even the development of these tight junctions 
are thought to be controlled largely by astrocytes [4, 8-10].  The surface of blood vessels 
in the brain are surrounded by a close network of astrocytic endfeet [9].  These endfeet 
are suggested to be involved in the maintenance and repair of the BBB.  In addition to 
glial cells, perivascular neurons (surrounding blood vessels) are involved in maintaining 
the BBB.  The combination of perivascular neurons, astroglia and endothelial cells are 
collectively known as the “neurovascular unit” [11, 12].  All components play an 
essential role in the selectivity, maintenance, and regulation of the BBB. 
BBB function is influenced by various neurotransmitter systems.  The water 
permeability of the BBB may be under the control of the noradrenergic system.  The 
stimulation of the locus coeruleus increases the water permeability[13].  In contrast, 
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blocking α-adrenergic receptors produces opposite results [13, 14].  Noradrenergic 
neurons, however rarely directly interact with the brain vascular walls but instead 
innervate the vasculature through the glia [15].  Neurotransmitters (glutamate, 
norepinephrine, dopamine and acetylcholine) are also thought to play a role in cerebral 
blood flow by the constriction or dilation of blood vessels.  Glutamate has been suggested 
to produce indirect vasodilatation of the smooth muscle cells in the cerebral vasculature 
by stimulating cells which surround the vasculature to release vasoactive factors [16, 17].   
Stimulation of noradrenergic neurons causes vasoconstriction and a reduction in cerebral 
blood flow [13]. Studies regarding serotonin involvement in cerebral blood flow indicate 
serotonin has a strong vasoconstriction effect, but also during some conditions this 
neurotransmitter may have a vasodilator effect [16].  Dopaminergic neurons cause 
vasoconstriction in both cortical slice preparations [18] and in situ [19].  Acetylcholine 
has been suggested to play a role in vasodilatation causing an increase in cerebral blood 
flow as was tested by stimulation of the basal forebrain, a major source of cholinergic 
perivascular innervation [20].  
Aquaporins 
Water permeability across the blood brain barrier has been studied extensively.  
Previously it was thought that water transport occurred solely by slowly dissolving 
through phospholipid bilayer and not by pores or slits [21, 22].   In other studies however, 
it has been suggested that in addition to diffusion though the plasma membrane water 
may move though small 12 Å pores within the endothelial cells [23]. Water passes 
through cells faster than expected via simple diffusion.  It is suggested that aquaporins 
(water channels) evolved to actively regulate rapid osmotic diffusion across the plasma 
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membrane in several tissues [24-26].  To date there are three major groupings of the 
aquaporin gene family: aquaglyceroporins, aquaporins and unorthodox aquaporins [27]. 
Aquaglyceroporins are responsible for movement of water, glycerol and other nonpolar 
solutes such as urea.  The aquaporin (AQP) group is responsible for movement of water 
only, while some unorthodox aquaporins are able to transfer ions as well as water. 
Currently four aquaglyceroporins (AQP3, AQP7, AQP9 and AQP10) five aquaporins 
(AQP0, AQP1, AQP2, AQP4 and AQP5) and four unorthodox aquaporins (AQP6, 
AQP8, AQP11 and AQP12) have been identified [26, 28, 29].  The entire aquaporin 
family of proteins can facilitate bidirectional transport and are found in tissues involving 
of water flux (Figure 1). Despite their different specificities all three groups have a 
similar structure with roughly 300 amino acids and six transmembrane domains (Figure 





















Of the three aquaporins found in the brain (AQP1, 4, 9) [33-36], AQP4 will be the 
focus of this thesis due to its relationship with the BBB and expression in astrocytes. 
Aquaporin 4, previously known as mercurial insensitive water channel (MIWC) [37, 38], 
is located on the plasma membrane of cells and is responsible for bidirectional flow of 
water in many tissues, including the brain [39-41].  Outside the brain, AQP4 is found in 
the kidney (principle cells), sarcolemma membrane of skeletal muscle myocytes, parietal 
cells of the stomach (basolateral aspect), salivary gland, lacrimal gland, colon (villus 
epithelium), trachea bronchi, iris, ciliary body, and neural cell layers in the retina [37, 
38].  In the brain AQP4 is predominantly found in astrocytes and ependymal cells, 
although some suggest AQP4 also may be present in endothelial cells [42], neurons, and 
Purkinje cells of the cerebellum [43]. 
The majority of AQP4 in the brain is polarized to astrocytic endfeet surrounding 
capillaries, areas lining the ventricles, and on the glia limitans [38, 44-52]. In areas where 
systemic osmotic regulatory control is necessary such as the supraoptic nucleus and 
subfornical organ, AQP4 is less polarized and is instead distributed along the entire 
astrocytic membrane [45]. While some have suggested AQP4 may have a role in 
osmoregulation [45], studies using AQP4 knockouts show no difference in serum 
osmolality indicating little evidence for AQP4’s role as an osmoregulatory effector [53]. 
Freeze fracture studies shows that AQP4 forms intramembranous square arrays 
termed orthogonal array of particles (OAP) [54].  Interestingly these square arrays were 
seen at astrocytic endfeet prior to the discovery of AQP4 and its role in water transport 
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[55-57]. Immunogold analysis has confirmed that the square arrays are complexes of 
AQP4 [58]. Early studies suggest that the assemblies disappear during periods of low 
oxygen [56].  
Aquaporin 4 is relatively insensitive to mercury unlike similarly structured AQP1 
[59].  A lack of cysteine at sites G94 and A210 in AQP4 is thought to be responsible for 
this phenomenon since these are the corresponding mercury inhibitory sites for AQP1.  
Substitution of cysteine for alanine at these locations in AQP4 retains mercury 
insensitivity suggesting that AQP1 and AQP4 structures are less homologous than 
initially assumed [43].  Creating cysteine substitutions, however at residues 70-73 and 
189 results in mercury sensitivity [59].  These findings suggest that the lack of cysteines 
near the aqueous pore (NPA, Figure 2), and not at homologous residues found in AQP1, 
is responsible for AQP4 mercury resistance [59].  
In astrocytes AQP4 forms protein complexes with other channels and proteins. 
Knockouts of α-syntropin decrease the polarity of AQP4 localization, showing a 90% 
decrease at astrocytic endfeet and increased immunostaining elsewhere. The loss of 
polarity is attributed to AQP4 association with α-syntropin since the total AQP4 protein 
expression remains unchanged.   The α-syntropin knockout shows no effect on AQP4 
localization in the kidney, brain ependymal cells and supraoptic nucleus [42].  Similarly, 
dystrophin-null mice show a drastic decrease in AQP4 localization at the endfeet while 
total brain AQP4 expression is unaltered.  These results suggest that AQP4 forms a 
complex with dystrophin with the use of an adaptor protein (α-syntropin) [41, 60, 61].  
Interestingly, the polarity of AQP4 also is strongly dependent on agrin (heparin sulfate 
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binding proteoglycan) suggesting that the entire α-syntropin, dystroglycan, agrin complex 
must be present in order to retain AQP4 polarity [52].    
Kir4.1channels also have been shown to colocalize strongly with AQP4 at 
astrocytic endfeet [61] and in rat retina cells [62].  The colocalization of Kir4.1 and 
AQP4 observed at the electron microscopy level of magnification suggests that AQP4-
mediated osmotic flux may be associated with potassium siphoning [62].  In α-syntropin 
null mice Kir4.1 immunoreactivity is only modestly reduced suggesting that Kir4.1 and 
AQP4 may not be bound to one another but are nonetheless adjacent.  Additionally, delay 
in potassium clearance is seen in α-syntropin null mice further suggesting a strong 
correlation of AQP4 and inward siphoning of potassium using the Kir4.1 channel [63].  




ATPase have been studied.  Strong 





ATPase lends additional support for AQP4’s involvement in potassium 
homeostasis and glutamate signaling as well as water transport [64]. 
2. Edema and Aquaporin  
Edema 
Brain edema is caused by an abnormal amount of fluid resulting in an increase of 
brain tissue volume.  There are two main types of brain edema, cytotoxic and vasogenic 
[65-67].  Cytotoxic brain edema is caused by water moving via an osmotic gradient, 
usually caused by a cellular metabolic dysfunction causing either intracellular 
hyperosmolarity or extracellular hyposmolarity [67].  During cytotoxic edema the BBB 
may remain fully intact.  In vasogenic edema however the BBB is disrupted. This may 
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occur from brain trauma, tumors or strokes [65].  Several animal models of vasogenic 
edema have been employed for research including fluid percussion, direct cortical 
contusion (either unilateral or bilateral) and focal freeze injury. The disruption of the 
BBB in these situations causes an increase in vascular permeability with an increase of 
fluid in the extracellular space due to extravasation of blood plasma.  Vasogenic and 
cytotoxic brain edema may occur simultaneously in pathological conditions [48-50, 68].   
Systemic hyponatremia may cause cytotoxic brain edema.  Decreased osmolarity 
within the lumen of the capillary causes an increased osmotic drive of water through 
endothelial cell membranes.  Once the hyposmotic solution crosses the endothelial cells, 
the extracellular space becomes hypotonic and water moves into the brain parenchymal 
cells.  Thus during cytotoxic edema, astrocytic endfeet processes surrounding capillaries 
begin to swell.  Transmission electron microscopy at the BBB shows an increase in the 
astrocytic end feet processes surrounding the brain capillaries from 0.73 +/- 0.10 µm
2
 to 
5.78 +/- µm 
2
 [69].  Osmotic brain edema is a common model used to induce cytotoxic 
brain edema in the laboratory.  During osmotic brain edema, a hyposmotic solution is 
injected intraperitoneally (IP) and is absorbed through the mesenteric vasculature.   This 
in turn causes the systemic hyponatremia throughout the organism resulting in cellular 
swelling in the brain [70].  Sodium and chloride efflux from the brain is greatest during 
the first thirty min of acute hyponatremia while a significant decrease in potassium is 
observed at three hours [71].   
During the initial stages of systemic hyponatremia, the brain may play a 
protective role by decreasing water permeability and through the reduction of total brain 
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osmolytes [70].  The loss of electrolytes in the brain is another symptom of 
hyponatremia. 
Animal models of stroke also cause cytotoxic edema [69]. However, in an 
ischemic brain both cytotoxic and vasogenic edema can be present.  Initially cytotoxic 
brain edema develops following cellular energy decrease due to the acute loss of glucose 
and oxygen.  After time, blood-brain barrier injury may lead to vasogenic edema[65]. 
Aquaporin 4 and edema 
AQP4 water permeability has been implicated in brain edema formation and 
resolution.  The role of AQP4 in cytotoxic and vasogenic brain edema has been explored 
by measuring AQP4 expression and localization.   
Cytotoxic brain edema  
Studies suggest that AQP4 protein expression rises significantly during cytotoxic 
brain edema but mRNA remains unchanged [44, 46, 47, 72]. During prolonged osmotic 
brain edema induced by IP water injection, a significant increase in AQP4 expression in 
whole brain to 164% and 153% of control values has been observed 4 and 48 hour after 
water injection respectively [44].  Cerebellar samples also showed a similar increase in 
expression when compared to control animals.  Analysis of AQP4 mRNA expression was 
used to evaluate the effect of water intoxication at the transcriptional level.  No 
significant increase was seen in AQP4 mRNA in either the whole brain or cerebellum 
after 4 hours of systemic hyponatremia [44].  Similar results showing an increase in 
AQP4 protein expression were seen during a transient middle cerebral occlusion, a model 
of pathology which causes both cytotoxic and vasogenic edema [65, 73]. 
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Cytotoxic brain edema also can be a consequence of acute liver disease [74, 75]. 
Increased expression of AQP4 is seen during cerebral edema induced by acute liver 
disease brought on by intraperitoneal injection of galactosamine, lipopolysaccharide and 
intravenous injection of ammonium-acetate [35]. An increase of brain water content from 
80.1% to 80.8% was correlated with an increase of AQP4 protein expression of 1.64 fold 
compared to control [35].  Similarly to previous experiments with cytotoxic edema 
induced by systemic hyposmotic hyponatremia [44], no change in AQP4 mRNA 
expression was observed.   In vitro studies with primary astrocytes also have 
demonstrated increased ammonia levels alone can enhance AQP4 protein expression [76, 
77].  
During osmotic brain edema water entering brain parenchyma must first cross the 
endothelial cell membrane before reaching the astrocytic cell membrane.   If the passage 
of water across the endothelial cell membrane was the rate-limiting factor, 
overexpressing AQP4 would cause no difference in the rate of water transport. 
Transgenic mice overexpressing AQP4 have been used to study the rate-limiting factors 
governing the development and resolution of cytotoxic edema. These animals showed a 
2.3 fold increase in AQP4 protein expression when compared to control mice [47].  The 
induction of osmotic brain edema caused an increase in brain swelling that was recorded 
within ten min of IP water injection.  Intracranial pressure ten minutes after injection was 
20 ± 2 mmHg in transgenic mice, 14 ± 2 mmHg in control mice and 9.8 ± 2 mmHg in 
AQP4 knockouts.  These data suggests that water transport into glial cells via AQP4 must 
be a rate-limiting factor for edema development in this animal model [47].    
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Microscopy also has shed light on AQP4 involvement during cytotoxic brain 
edema.  Increased AQP4 immunoreactivity of the hippocampus was observed after 90 
min of water intoxication [46]. Immunostaining of AQP4 was more widespread and 
diffused in the hippocampal region than in control animals.  Additionally, staining around 
vessels was spotty and less polarized, making vessels appear longer and thicker during 
edema [46].  Similar AQP4 immunoreactivity has been seen in spontaneously 
hypertensive rats as in rats with cytotoxic brain edema [72].  Consistently, induction of 
brain edema with an intact blood-brain barrier has showed an increase in immunostaining 
and immunoblotting of AQP4 protein with little change to mRNA levels. 
Some authors suggest that immunohistochemistry provides a poor evaluation for 
analysis of AQP4 distribution.  Vajda et al. [44]  suggest that light and electron 
microscopy cannot be used to determine AQP4 redistribution on the plasma membrane 
facing the capillaries, but freeze fracturing must be done because it is uncertain if AQP4 
redistribution occurs under standard microscopy [44, 54]. 
In a related study, animals with the α-syntropin knockout have decreased polarity 
of AQP4 at the perivascular membrane of glial cells by as much as 90% and show a delay 
in edema formation during hyponatremia [42]. The α-syntropin knockout seems to only 
be associated with AQP4 found on astrocytic membrane since total brain AQP4 is 
unaffected. Dystrophin null mice produced a similar mislocalization of AQP4 and a 
delayed onset of osmotic brain edema [60].   These results suggest that AQP4 localization 
and polarization are crucial for osmotic edema development and thus, could be a target 
for drugs to delay onset of edema [42]. 
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Aquaporin 4 knockout and cytotoxic edema 
Knockout studies involving both cytotoxic and vasogenic brain edema have shed 
light on AQP4’s role for brain volume regulation. In this genetic model, little or no 
change in tissue, organ development, neuromuscular function, or survival of mice has 
been shown [53].  Additionally, expression of other aquaporins such as 1, 2, 3 and 5 were 
not affected and no change in BBB integrity or morphology has been seen with AQP4 
gene deletion [78].  No tight junction misformation, myelination, increased intercranial 
pressure or alterations in vascular anatomy were noted by several sources [69, 78-80].  
Interestingly though, one study has shown evidence for decreased GFAP expression and 
open cerebral endothelial tight junctions in AQP4 knockout animals [33]. 
During cytotoxic brain edema AQP4 may play a detrimental role for animal 
survival while during vasogenic edema, AQP4 may be involved in removing excess fluid 
from the brain and thereby increasing the chances of survival [69].   Compared to 
wildtype mice, knockouts show a decrease of swelling in the astrocytic feet processes and 
water content in the brain after 30 min of acute water intoxication [69].  Additionally, 
AQP4 knockout animals show less of an increase in intracranial pressure during osmotic 
brain edema when compared to wild type mice [81].  Null mice also showed a delay in 
the increase of intracranial pressure.  This delay could correlate with decreased water 
accumulation caused by lowered BBB osmotic water permeability in the AQP4 null 
animals. 
In an ischemic stroke model of cytotoxic brain edema using permanent middle 
cerebral artery occlusion, AQP4-deficient mice had decreased hemispheric enlargements 
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(35%)  and infarct volume [69]. Increased chance of survival and improved neurological 
scores also were observed in AQP4 knockout mice [69]. In cultured astrocytes similar 
results were seen during cell swelling.  In astrocytes containing AQP4, cell volume was 
significantly higher than for AQP4 knockout mice during oxygen and glucose-
deprivation induced swelling.  Reoxygenation after six hours of oxygen and glucose 
treatment however, returned the cell volume back to control levels two days faster in 
AQP4
 
wildtype mice [39].  These data suggests that AQP4 is a key player for both influx 
and efflux of water in astrocytes. 
In pneumococcal meningitis, where cytotoxic edema is thought to predominate 
over vasogenic edema, AQP4 also plays a detrimental role.  Wildtype mice showed a 
fivefold increase in water permeability in the brain causing elevation of both intracranial 
pressure and water content.  AQP4 null mice showed signs of infection but remarkably 
little change in intracranial pressure during meningitis [79].   
In summary, during systemic hyponatremia the accumulation of brain water is 
significantly decreased in AQP4 knockout mice.  AQP4 may play a pivotal role in 
osmotic permeability into brain parenchyma and its deletion has been shown to decrease 
the rate of development of cytotoxic brain edema.   
Vasogenic brain edema  
Various changes in AQP4 expression have been reported during vasogenic brain 
edema.  However, it is important to note that during vasogenic brain edema, cytotoxic 
brain edema also may be present.   
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Several cortical impact models have reported AQP4 protein and mRNA changes 
during the evolving edema.  Both a decrease [48, 49, 68] and increase [49, 50, 82] in  
AQP4 immunoreactivity has been observed on the damaged side of the brain. 
In a controlled cortical impact model, where one hemisphere of the brain is 
damaged, AQP4 protein and mRNA expression decreased significantly one day after the 
cortical contusion injury in the ipsilateral damaged hemisphere. [48, 68].  In the 
contralateral hemisphere however, there was no change in AQP4 protein or mRNA 
expression at this time point [48, 68], while a significant decrease in AQP4 protein was 
observed 48 hours after injury [68]. Confocal microscopy findings were consistent with 
the results of lowered AQP4 protein expression at the contusion core 24 hours after 
injury. Semi-quantitative immunohistochemistry using confocal microscopy showed a 
decrease in AQP4 immunoreactivity in the brain following a controlled cortical contusion 
injury at the impact site; however, an increase in AQP4 immunoreactivity was seen in 
surrounding areas [49].  A possible functional explanation for the immunoreactivity 
finding is that AQP4 in the surrounding contused area is up-regulated to buffer the 
increase in interstitial fluid. 
Other studies with opposite findings have been published regarding AQP4 protein 
expression in cortical impact injury.  One study showed an increase in both AQP4 
expression and water content on the injured side of the brain [82].  Additionally in a 
bilateral controlled cortical model, AQP4 protein expression was significantly increased 
in the area immediately surrounding the contusion after 72 hours but not after 24 hours. 
AQP4 expression was not measured at the core of the contusion [50].   The differences in 
these finding may be a result of differences in the location of tissue sampled relative to 
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the contused area.  Additionally the extent of injury and time of tissue extraction after 
injury may be important.  Previous reports suggest that maximal brain edema following 
cortical contusion injury appears between 24 and 72 hours [83, 84]. During this time, 
AQP4 expression may be fluctuating, thus leading to inconsistent finding between labs. 
AQP4 protein expression is altered by several drugs which decrease formation of 
brain edema.  In both a middle cerebral artery occlusion and cortical contusion injury 
animals receiving SR49059 (V1a vasopressin antagonist) treatment immediately after 
injury showed a significant decrease in both AQP4 protein expression  and water content 
compared untreated injured animals [73, 82].  In the bilateral contusion model, a similar 
decrease of AQP4 protein expression lessened the brain edema in progesterone-treated 
animals compared to untreated injured animals [50].   
In the cortical contusion injury model, injection of sulforaphane, a possible 
anticancer drug, six hours after injury caused a smaller decrease in AQP4 
immunostaining at the contusion core compared to injury only animals.  Furthermore 
AQP4 immunostaining significantly increased in areas surrounding the contusion 24 and 
72 hours after injury in sulforaphane treated animals. This could suggest a possible use of 
sulforaphane to increase AQP4 expression during vasogenic edema.  To test this theory 
brain water content was measured 24 hours and 72 hours after brain injury.  Animals that 
were injected with sulforaphane after injury showed a significant 0.64% decrease in total 
brain water content only three days after injury compared to non-sulforaphane treated 
animals [49].   
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Additional publications reported results using a cerebral artery occlusion to model 
vasogenic edema.  In immature and juvenile rats with a permanent right carotid artery 
occlusion and induced hypoxic environment, AQP4 immunostaining but, not AQP4 
protein expression, was decreased 1 hour and 24 hours after injury [51].  This difference 
in relative change in AQP4 expression using immunohistochemical and western blot 
techniques suggests that changes in immunostaining may not be a result of changes in 
protein expression, but rather caused by altered protein conformation since there was no 
change in total AQP4 protein expression. In a transient (30 min) middle cerebral artery 
occlusion model however, an increase in AQP4 expression was observed one hour after 
ischemia (30 min after reperfusion) in the ipsilateral cortex [85].   
Several other drugs also have been used in an attempt to reduce vasogenic edema 
after transient artery occlusion. Low dose thrombin injection prior to ischemia caused an 
increase in AQP4 expression (both immunostaining and immunoblotting) compared to 
untreated ischemic mice only [85].  Immunohistological results suggest that the increase 
in protein expression is localized at the perivascular endfeet of glial cells. Brain water 
content increase also was lessened by thrombin treatment.   Thrombin treatment suggests 
a protective role in vasogenic brain edema with increased expression of AQP4 in the 
ipsilateral ischemic hemisphere; however, thrombin treatment prior to stroke did not 
prevent early disruption of the BBB.  Taken together thrombin treatment does not reduce 
edema by altering the BBB but by promoting water clearance from the extracellular 
space.  In this study it is important to note that the increase in AQP4 expression did not 
worsen edema [85] .         
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An agonist for adrenergic and imidazoline receptors, agmatine, has been shown to 
decrease both brain edema volume and water content after transient middle cerebral 
artery occlusion independent of AQP4 expression [86].   Aquaporin 4 immunoblotting 
was not significantly different between control and treatment groups.  AQP1 expression 
however was limited by agmatine suggesting that the decrease in brain edema was caused 
by agmatine’s role in down regulating AQP1 expression.     
In summary, AQP4’s involvement during vasogenic edema may be different 
during arterial occlusion and cortical impact injuries.  AQP4 expression and 
immunoreactivity changes are altered with vasogenic edema.   Studies using agents to 
either increase or decrease AQP4 expression have shown these treatments decrease 
intracranial pressure and edema volume.  Knockout studies however, provide additional 
insight in AQP4 involvement in developing vasogenic edema. 
Aquaporin 4 knockout and vasogenic brain edema 
AQP4 knockout studies have played an important role in determining AQP4 
involvement in vasogenic brain edema.  Overall, AQP4 knockout animals display higher 
intracranial pressures, edema volume, and worsened neurological scores after induced 
vasogenic edema.   
Intracerebral fluid infusion (IFI), focal cortical freeze injury (FCI) and tumor 
(melanoma) cell implantation (TCI) demonstrated higher intracranial pressure (ICP) in 
AQP4 knockout mice compared with wildtype after brain injury [87]. Total water content 
also increased more in knockout animals compared to injured wildtype animals following 
the intracerebral fluid infusion and focal cortical freeze injury models. In the tumor cell 
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implantation model AQP4 null mice showed greater neurological deterioration.  In 
addition, neurological scores decreased in all knockout animals compared to wildtype 




Table 1.  Three vasogenic models performed on wild type and aquaporin 4 knockout 
mice from results of Papadopoulos et al. 2004. Data are presented as mean ± SEM. 
Intracerebral fluid infusion (IFI), focal cortical freeze injury (FCI) and tumor cell 




Model AQP4 Knockout Wildtype 
ICP (cmH2O) % Brain 
Water 
ICP (cmH2O) % Brain 
Water 
IFI 52 ± 6 81.2 ±  0.1 26 ± 3 80.4 ± 0.1 
FCI 22 ± 4 80.9 ± 0.1 9 ± 1 79.4 ± 0.1 
TCI 39 ± -5 NA 19 ± 4 NA 





The same lab investigated focal vasogenic edema induced by a staphylococcal 
brain abscess.  The brain abscess size was similar in wildtype and AQP4 knockout mice 
and intracranial pressure and water content were elevated during edema in both groups. 
However, the AQP4 null mice showed a significant increase in both intracranial pressure 
and water content compared to controls [88].  Additionally AQP4 wildtype mice with 
brain abscess showed a significant increase in AQP4 immunostaining around the focal 
edema when compared to controls.  Thus, AQP4 may provide a similar protective role in 
bacterial abscess as in a tumor-induced vasogenic edema.   
In summary, AQP4 deletion is detrimental during vasogenic edema caused by 
focal freeze injury, intraparenchymal injection, and focal tumor/bacterial induction.  
These results suggest that AQP4 plays a role in transporting water from the brain 
parenchyma to intraventricular and subarachnoid compartments as a protective survival 
mechanism.    
3. Regulation of aquaporin 4 
Ontogeny of AQP4 expression differs among species. In rodents, AQP4 protein 
expression develops in the brain just after birth while in birds AQP4 expression can be 
seen prenatally [43, 89, 90].  In the rat cerebellum, AQP4 protein expression is 25% of 
that in adults after 14 days postnatal [90].  A 9 day chick embryo already shows high 
levels of AQP4 immunoreactivity surrounding immature tight junctions of endothelial 
cells, suggesting an important role in BBB integrity [89]. Although there is strong 
evidence of long-term regulatory function of AQP4 development, the focus of this thesis 
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will center on treatments which affect the regulatory mechanism of the water channel in 
adult rats.   
As expected, the water permeability of cultured astrocytes containing AQP4 is 
significantly greater than that of cells without AQP4 [91, 92].  Several studies shed light 
on AQP4 regulation and its involvement in swelling at a cellular level.  Increased 
ammonia levels alone can increase AQP4 expression in astrocytes in vitro [76, 77].  
Cultured astrocytes showed no volume change within 11 hours of ammonia treatment but 
increased by 32% and 76% at 12 and 18 hours, respectively [77]. AQP4 expression also 
remained steady and increased only after 10 hours.  AQP4 expression and cell volume 
showed a strong correlation (r=0.95) during the 12-48 hour treatment periods.  These 
results suggest that AQP4 protein expression is time dependent in cells treated with 
ammonia.   
When oocytes express AQP4, a 15-fold increase in water permeability during 
hyperosmotic treatment is observed [93].  Oocytes coexpressing AQP4 and V1αR 
(arginine vasopressin receptor 1A) showed a decrease in water permeability during 
vasopressin exposure [93]. Thus an association between AQP4 and V1αR may regulate 
water permeability change in response to vasopressin. A 65% reduction in capacitive 
currents were observed in oocytes containing AQP4/ V1αR during vasopressin exposure 
suggesting that the change in water permeability was caused by internalization of AQP4.   
Hormones also play a role in regulation of AQP4 expression.  Treatment with 
testosterone, but not 17β-estradiol or dexamethasone (synthetic steroid) has been shown 
to increase AQP4 protein and mRNA expression in cultured astrocytes [94]. 
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In transgenic mice, overexpression of endothelin-1 (potent vasoconstrictor) 
induces AQP4 protein expression causing an increase in water content in the brain after 
induction of osmotic brain edema [46]. However treatment with OPC-31260 (vasopressin 
V2 receptor antagonist) reduced the effects of osmotic brain edema.  Additionally after 
treatment with OPC-31260, AQP4 immunoreactivity and protein expression was 
diminished at the astrocytic endfeet suggesting a role of V2 receptor as a mediator of 
AQP4 during edema [46]. 
Aquaporin 4 and p38mitogen-activated protein kinase (MAPK) 
Mannitol treatment causes an increase in AQP4 expression in vivo and in vitro 
and was used to determine the role of MAPK inhibition on AQP4 expression [24]. In 
cultured rat astrocytes an increase in AQP4 mRNA expression was observed for 12 hours 
after treatment. AQP4 mRNA levels returned to normal after 24 hours. AQP4 protein 
expression increased within an hour and then remained constant over a period 48 hours.  
This suggests transcriptional and post-transcriptional factors may influence AQP4 protein 
expression.  A p38 MAPK inhibitor reduced expression of AQP4 protein and mRNA in 
vitro.  The reduction of AQP4 expression suggests that regulation of AQP4 is partly 
dependent on the p38 MAPK pathway. Phosphorylation and activation of p38 MAPK 
was observed during hyperosmotic stress in cultured astrocytes [24].  
Aquaporin 4 and protein kinase C (PKC) 
AQP4 protein and mRNA expression also may be regulated by PKC in cultured 
astrocytes [94-96]. Activation of PKC by tetradecanylphorbol acetate (TPA) causes a 
decrease in both AQP4 protein and mRNA expression while pretreatment with PKC 
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inhibitors (H7 and chelerythrine) attenuates the effects of TPA [95]. Additionally, PKC 
activation using TPA decreased the heightened AQP4 expression that is caused by 
testosterone [94].  
Studies using oocytes [93, 97] and epithelial cells also suggest that AQP4 
involvement in water permeability is regulated by PKC. In oocytes, PKC activators 
(phorbol 12, 13-dibutyrate and phorbol 12-myristate 13-acetate PMA) decreased AQP4 
activity and reduced the rate of swelling in a hyposmotic solution [93, 97]. Furthermore 
increased phosphorylation of AQP4 following PMA treatment suggests regulation of 
AQP4 is controlled by protein phosphorylation [97].  Additional electron microscopy and 
immunocytochemistry examination suggests that activation of PKC caused AQP4 
internalization in oocytes [93, 98]. In cultured kidney epithelial cells AQP4 
phosphorylation at Ser
180
 by PKC activation is thought to decrease AQP4 permeability. 
No AQP4 internalization or delocalization was observed suggesting that in this case 
decreased AQP4 permeability is directly altered by phosphorylation [28].   
Since PKC has been shown to regulate AQP4 expression [93-95, 97], PKC 
activators have been used to control the onset of brain edema in two pathological models 
[99, 100].  In one study, animals treated with phorbol ester (PKC activator) 30 in after 
contusion showed decreased brain water content [99].  In a separate study in which 
edema was induced via middle cerebral artery occlusion, AQP4 expression was decreased 





Aquaporin 4 and protein kinase CK2 
Protein kinase CK2 phosphorylation at the c-terminus of AQP4 has been 
proposed as a signal for trafficking the protein to the plasma membrane [102, 103]. In 
cultured mouse astrocytes, AQP4 is constitutively phosphorylated by protein kinase CK2 
at multiple sites on the c-terminal domain [102]. Disrupting phosphorylation by CK2 









) causes AQP4 accumulation by the Golgi apparatus [102].  Thus, the 
phosphorylation of AQP4 by CK2 is suggested to be necessary at the Golgi apparatus or 
endoplasmic reticulum prior to exiting the Golgi.   
In epithelial MDCK cells expressing AQP4, phosphorylation via the CK2-
dependent pathway also thought to play a role for the protein degradation signaling 
pathway [103]. The phosphorylation of Ser
276
 leads to increased interaction of a 
lysosomal marker suggesting regulation of CK2 is used to traffic the protein to lysosomes 
[103].  Thus the CK2 pathway may provide a regulatory means of cell surface expression 
of AQP4. 
Aquaporin 4 and protein kinase A (PKA) 
In cultured human gastric cells, histamine treatment causes AQP4 
phosphorylation and internalization followed by storage in late endosomes [104]. Once 
histamine is removed, AQP4 relocates to the plasma membrane. A threefold increase in 
PKA and PKC activity is seen during histamine treatment [104]. Inhibition of PKA but 
not PKC reduced AQP4 phosphorylation after histamine treatment. Inhibition of PKA 
however did not prevent internalization, suggesting that AQP4 phosphorylation occurs 
after internalization.  Thus, AQP4 phosphorylation via PKA inhibits degradation after 
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internalization.  By this process AQP4 is stored in a vesicular compartment and is readily 
available for recycling to the plasma membrane. 
Aquaporin 4 and protein kinase G (PKG) 
In astrocyte cell cultures, glutamate has been shown to increase water 
permeability possibly as a result of activation of group I metabotropic glutamate 
receptors (mGluR) [105]. The group 1 mGluR agonist, DHPG, caused an increase in 
water permeability of astrocytes containing AQP4 and an intracellular calcium response, 
while an NMDA receptor agonist showed no effect. Additionally increased water 
permeability caused by DHPG was abolished after adding the PKG inhibitor (H-89). 
Taken together, the increase in astrocyte water permeability is calcium dependent and 
may be mediated by PKG phosphorylation of AQP4 [105].     
Aquaporin 4 and calmodulin-dependent protein kinase II (CaMKII) 
Cultured astrocytes containing AQP4 show an increase in water permeability 
upon lead intoxication but no effect of lead is seen in cultured astrocytes that are AQP4 
deficient [92]. Introduction of a CaMKII inhibitor (KN-62), but not PKC inhibitor 
(bisindolylmaleimide), attenuated the effect of lead on water permeability [92]. When a 
potential CaMKII phosphorylation site, Ser
111
 was mutated, KN-62 had no effect on the 
lead-induced increase in water permeability. The finding using KN-62 suggests that lead 
may activate CaMKII to phosphorylate AQP4 at Ser
111
 resulting in increased water 




4. Blood-brain barrier water permeability  
Blood-brain barrier water permeability is altered during osmotic brain edema and 
treatment with tricyclic antidepressants [70, 106].  
Osmotic brain edema 
 Osmotic brain edema is a common model of cytotoxic brain edema.  Water is 
injected into the peritoneal cavity which induces system hyponatremia.  Brain water 
content, water permeability, and cerebral blood flow was studied during two hours of 
osmotic brain edema induced by this treatment [70].  Brain water content increased in the 
cerebral gray and white matter after two hours of edema.  Additionally, water 
permeability and blood flow were decreased one and two hours after treatment at which 
point swelling of the astrocytic endfeet was observed [107].  In summary, data suggest an 
increased resistance to osmotic water flux after osmotically induced cerebral brain edema 
[70]. 
Tricyclic antidepressants (TCA) 
TCA are often used to treat depression mainly by increasing the levels of 
norepinephrine and serotonin in the brain.  The general mechanism of TCA action 
involves downregulating norepinephrine and serotonin transporters located on the 
presynaptic terminal of neurons [108].  These selective transporters are responsible for 
reuptake of neurotransmitter after it is released into the synaptic cleft. In addition, chronic 
use of TCA has been shown to downregulate adrenoreceptors on the post synaptic neuron 
[109, 110].  The combination of the inhibition of selective transporters and 
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adrenoreceptors allow TCA to be used as agents to determine the role of noradrenergic 
systems in the brain. 
Several studies suggest a role of the noradrenergic system for regulating brain 
capillary permeability [13, 111, 112].  To investigate the regulatory function of the 
noradrenergic system, TCAs were administered to animals and cerebral capillary 
permeability was measured. Acute treatment of several drugs in this class (doxepin, 
amitriptyline, imipramine, nortriptyline, desipramine, and protriptyline) were 
administered and cerebral capillary permeability was measured five minutes later.  TCA 
administration caused a significant increase in cerebral capillary permeability [106].  
Animals treated with amitriptyline (AMI) daily for two weeks had a significant increase 
in capillary permeability following this chronic treatment.  The increase in permeability 
was significantly higher in the chronic treatment group compared to the acutely treated 
animals [113].  These studies show that TCA treatment has a potent effect on the 
permeability of brain vasculature, suggesting a strong noradrenergic regulatory 
involvement in AQP4 function. 
5. Summary 
A change in cerebral capillary water permeability occurs during osmotic brain edema 
and chronic treatment of tricyclic antidepressants.  The change in water permeability 
during these two models may result from a change in AQP4 expression and distribution 
at the astrocytic endfeet.  Alterations in AQP4 expression and distribution may be a result 
of changes in levels of neurotransmitters and phosphorylation of serine residues on the c-
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terminus of AQP4.   Our goal of this thesis is to determine AQP4 expression and 





















This research is designed to address the question of whether or not aquaporin 4 
expression and distribution is altered by two treatments that are known to change water 
permeability in the brain.  Our hypothesis is that regulation of aquaporin 4 
localization and expression controls physiological water permeability at the blood 
brain barrier.   
Specific Aims 
1) Observe AQP4 expression and distribution in animals undergoing osmotic brain 
edema. 
2) Observe AQP4 expression and distribution in animals undergoing chronic 





















This study was approved by the Laboratory Animal Care and Utilization Committee 
of Wright State University and conformed to the Guide for the Care and Use of 
Laboratory Animals. Twenty-eight adult male Sprague Dawley rats between 168-291 
grams were used for the study.  Animals were housed at the Laboratory Animal Care 
facilities at Wright State University.  All surgical procedures and analyses were 
performed at Cox Institute in Kettering Ohio. 
Animal preparation and surgical procedures 
Modified methods from Olson et al were used [70]. Animals were exposed to 5% 
isofluorane in a 5-liter container.  After anesthesia was induced, the animal was 
transported to an operating table and a face mask (Harvard Apparatus) was fitted flowing 
2% isofluorane mixture in medical-grade air.  Anesthesia was monitored and altered if 
needed to ensure proper surgical anesthesia levels.   A rectal probe and a 24 gauge 
femoral arterial catheter with a heparin filled polyethylene tube were inserted to measure 
core body temperature and blood pressure respectively.  Temperature, arterial blood 
pressure, and heart rate were monitored throughout the surgery.     
The experiment contained three animal groups, water-injected, desipramine 
treated and control.  In the water-injected group, osmotic brain edema was induced 
during surgical anesthesia.  These animals received an intraperitoneal injection of 
distilled water at room temperature equivalent to 15% of the body weight.  The second 
group received no water injection but was given intraperitoneal injections of desipramine 
(10 mg/kg) daily for two weeks prior to induction of surgical anesthesia.  In the control 
group, animals underwent surgery and were anesthetized similar to the water-injected 
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group but were not injected with water. All animals were monitored for two hours under 
anesthesia.   Blood samples were collected at the beginning of the experiment and at 15, 
30, 60, 90 and 120 min after the animal was hemodynamically stable. Blood osmolality 
was measured in each blood sample while the hematocrit levels were obtained at the 0 
and 120 minute time points.  Blood osmolality was measured by a vapor pressure 
osmometer (Wescor 5500, Salt Lake City, UT).  Hematocrit levels were assessed after 
centrifugation (Clay-Adams Micro-Hematocrit, New York City, NY) After 120 min 
animals were either perfused with fixative or rapidly decapitated while under anesthesia.  
Circulatory perfusion was performed following thoractomy.  The right auricle was 
severed and a 16 gauge tube was placed through the left cardiac ventricle.  Animals were 
first exsanguinated by perfusion of 200 ml normal saline followed by 200 ml of 4% 
paraformaldehyde in 0.085 M phosphate buffer under a pressure of approximant 1 m of 
water at the cardiac ventricle.  Other rats were decapitated without circulatory perfusion, 
for these animals the brains were removed for analysis of water content and AQP4 
expression. 
Brain water analysis 
After decapitation and rapid dissection from the skull, the brain was divided along 
the sagittal fissure.  The cortex of one hemisphere was removed from the underlying 
brain stem using a stainless steel spatula.   
All brain tissues were placed in preweighted porcelain crucibles and weighed to 
determine the brain wet weight.    Specimens then were placed in an oven for 48 hours at 
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105° C.  The crucibles were reweighed to determine the brain dry weight and the percent 
total water content was calculated from the formula, 
 Percent water content = brain wet weight – brain dry weight   x 100% 
      brain wet weight 
  Four animals from each group were used to determine percent water content. 
Tissue extraction and preparation for protein analysis  
The cerebral cortex not used for rain water analysis was promptly dissected from 
the diencephalon and placed in liquid nitrogen.  Samples then were stored at -70°C until 
processing.  Roughly 70 mg of tissue was homogenized in 1 ml lysis buffer (FNN0071, 
Invitrogen, Carlsbad, CA) containing 1 µm dithiothreitol and protease inhibitor cocktail 
(P2714, Sigma-Aldrich, St. Louis, MO) using a glass hand homogenizer. The 
homogenized samples were allowed to incubate on ice for 10 min prior to a 5 min 
centrifugation at 12,000 x g.  The protein-containing supernatant lysate then was used for 
protein assay using bicinchoninic acid BCA method, and for western and dot blot 
analysis. Three day-old neonatal rat liver tissue was used as a negative control and was 
processed using the same homogenization and lysis technique. 
Protein assay 
Ten microliters of each brain lysate were combined with 90 µl of water in 1 ml 
BCA solution (Sigma Aldrich, St Louis, MO).  Standards and tissue lysates then were 
incubated for 25 min at 40°C. Sample optical densities at 560 nm minus that at 650 nm 
were analyzed using a Universal Micro Plate Reader (ELx800).  The standard protein 
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concentration curve using bovine serum albumin was used to determine the total protein 
concentration of each lysate sample. 
Polyacrylamide gel electrophoresis and membrane transfer 
Methods used were modified from Vajda et al and Tomassoni et al [44, 72].  
Brain lysate (15 or 30 µg protein) was mixed with 20 µl of Laemmli standard buffer 
(161-0737, Biorad, Hercules, CA) containing either β-mercaptoethanol or dithiothreitol 
(5%, 10% or 40%).   Samples were heated for 9 min at 95° C and loaded onto 10% 
precast gels (Mini-Protean 456-1034 Biorad, Hercules, CA).  Electrophoresis was run at a 
constant 100 V for 80 min.  Following electrophoresis, proteins were transferred to 
PVDF membranes for 18 hours at 50 mA.   
Western blot analysis 
Methods were modified from Oliva et al. [114]. Following protein transfer PVDF 
membranes were rinsed for 10 min with TTBS consisting of 0.15 M NaCl, 0.02 M Tris-
HCl, and 0.05% Tween-20, pH 7.5.  The membranes then were blocked in 5% non-fat 
dry milk (170-904, Biorad Hercules, CA) for one hour followed by 4 five minute washes 
in TTBS.  Membranes were incubated overnight in primary antibodies for either 
aquaporin-4 (1:5000, AB2218, Millipore, Billerica, MA) or β-actin (1:5000, 600-401-
886, Rockland, Gilbertsville, PA).  After overnight exposure, a series of four washes was 
done in TTBS followed by one hour incubation in HRP-conjugated secondary (1:25,000, 
170-5046, Biorad, Hercules, CA).  A final series of rinses was done with TTBS.  Blots 




Dot blot analysis 
Nitrocellulose membranes (162-0168, BioRad, Hercules, CA) were submerged in 
transfer buffer (25 mM Trizma base, 192 mM glycine and 0.5% sodium dodecyl sulfate) 
prior to sample loading.  A single membrane was loaded into a vacuum filtration 
manifold system with 20 wells (Gibco BRL 11055, Life Technology).  An equal amount 
of brain protein (50 µg) was loaded into each well of the apparatus and vacuum was 
engaged.  To serve as positive control 0.5 µg AQP4 control peptide (AQP41-p, Alpha 
Diagnostics, San Antonio, Texas) was loaded in some wells. After ten min the vacuum 
was removed and the membrane was washed in TTBS.  The membrane then was blocked 
in 5% non-fat dry milk (170-904, Biorad, Hercules, CA) for one hour followed by 4 five 
minute washes in TTBS.   
Membranes were incubated for one hour in primary antibodies for either AQP4 
(AB2218, Millipore, Billerica MA) or β-actin (600-401-886, Rockland, Gilbertsville, 
PA). For one membrane AQP4 primary antibody was pre-absorbed using an equal 
amount (by mass) of AQP4 control peptide.  After one hour of incubation, a series of four 
washes was done in TTBS followed by one hour incubation in HRP-conjugated 
secondary (170-5046, Biorad, Hercules, CA).  A final series of rinses was done with 
TTBS.  Blots were imaged using ECL substrate on a Fujifilm LAS-3000 
chemiluminescence imager.  Band intensity was measured in arbitrary units and was 
corrected for the local background by subtraction. A total of 4, 3 and 5 rats were used in 




Tissue preparation and cryosectioning for immunohistochemistry  
Following perfusion fixation of the animal, the calvaria was carefully removed to 
expose the brain.  The brain was dissected from the skull and placed in 4% 
paraformaldehyde in 0.095 M phosphate buffer for two hours.  After 2 five minute rinses 
in phosphate-buffered saline (PBS) the brains were stored in PBS containing in 30% 
sucrose at 4° C until cryosectioning.   
Prior to cryosectioning the tissue was transferred to 1:1 mixture of PBS and tissue 
embedding media (SH75-125D, HistoPrep TM) for 30 min.  Then, the tissue was fully 
submerged in the embedding media.  Brains were sectioned coronally at 20 µm in the 
mid-frontal region.  Brain sections were mounted on glass slides and stored at -70° C 
until staining.   
Immunohistochemical staining 
Modified methods from Tomassoni et al were used [72].  Slides from each 
treatment group were stained on the same day.  Slides containing 20 µm brain sections 
were washed in a PBS-T solution consisting in 1% Triton X-100, 1 M Na2HPO4, 144 mM 
NaCl pH 7.42. Following 2 five min rinses the sections were soaked in a PBS-T 
containing 1% paraformaldehyde for 30 min.  Sections were rinsed in PBS-T and then 
soaked for 30 min in PBS-T containing 1 mg/ml sodium metaborate (10555-76-7, Sigma 
Aldrich, St. Louis, MO) to decrease autofluorescence. A third series of rinses was 
performed with PBS-T and the sections were soaked in 20% normal goat serum (005-
000-121, Jackson Immuno Research, West Grove, PA) for 15 min.  The sections were 
incubated with primary antibodies at 4°C overnight. Three primary antibodies were used 
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for immunohistochemistry; mouse anti-glial fibrillary acidic protein (1:750, SMI-22, 
Covance, Lutherville, MD), mouse anti-blood brain barrier protein (1:1000, SMI-71, 
Covance, Lutherville, MD) and rabbit anti-aquaporin-4 (1:500, AQP41-S, Alpha 
Diagnostic, San Antonio, Texas).  The next day the slides were rinsed and probed with a 
secondary antibody conjugated with a fluorescent molecule.  Either Alexia Fluor 555 
(1:500 Invitrogen) or FITC (1:100, 111-095-144, Jackson Immuno Research, West 
Grove, PA) was used to visualize the anti-AQP4 antibody while FITC (1:100, 115-095-
062, Jackson Immuno Research, West Grove, PA) was used to visualize anti-blood-brain 
barrier and anti-GFAP antibodies.  A final rinse with PBS-T to remove unbound 
antibodies was completed followed by a deionized water wash.  Sections were preserved 
in mounting media (17985-10, Electron Microscopy Sciences) with an overlying cover 
slip. Images were acquired using both laser confocal and epifluorescence microscopy.   
Epifluorescence and confocal laser microscopy 
Fluorescence microscopy was used to determine the location of AQP4, the SMI-
71 blood-brain barrier associated protein and GFAP in the brain.    Epifluorescence 
images were captured using Olympus BX51 and Nikon Eclipse E600 microscopes.  
Images were analyzed using Image J 1.37C.  Confocal microscopy was performed using 
a Nikon Eclipse C1 Plus system containing three lasers to determine the 
immunoreactivity of AQP4 at the glial endfeet surrounding capillaries.  Laser lines of 488 
nm (for FITC) and 561 nm (for Alexa Fluor) were used to excite the fluorescent labeled 
antibodies.  A photo-multiplier detector (PMT) was used to detect fluorescence emission 
at 450 ± 25 nm, 525 ± 25 nm, and 595 ± 25 nm.   NIS Elements Advanced Research 3.20 
software was used to analyze images.   
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A structured method to analyze AQP4 localization was employed (Fig 3).   In 
each section four regions of interest (ROI) were selected in the cerebral cortex near the 
saggital fissure.  A z-stack of roughly sixty images separated by 0.2 µm was acquired.  
The image in each z-stack containing the highest mean intensity of immunoreactivity was 
selected for analysis.  At the selected z-plane, the four strongest stained capillaries cut in 
cross section were analyzed using a linear intensity profile.  The resulting histogram of 
pixel intensities was evaluated by determining the maximum pixel intensity and 
normalizing this value to the average intensity of five pixels in the adjacent background 
(Figure 3D).  Four 20 µm sections were analyzed for each animal. Thus, intensity profiles 
of 48-64 capillaries were recorded for each animal. Each animal’s average intensity 
profile was then average within the treatment group.  These normalized intensities were 
then averaged to give a single measure of relative AQP4 immunofluorescence for each 
animal.  Three animals from each group were used for immunohistochemistry. 
Statistical analysis 
Significance was considered for p values lower than 0.05.  Repeated measure 
ANOVA with post-hoc Dunnett’s test was used to evaluate changes in blood osmolality. 
Student’s t-test was done to evaluate changes in brain water content.  Independent 
Student’s t-tests were  used to compare each treatment group to controls for analysis of 
initial plasma osmolality, hematocrit, heart rate, blood pressure and temperature. 
ANOVA single factor analysis at (alpha 0.05) was used for the analysis of initial 
hematocrit and osmolality between groups.  To compare ratios of maximal intensity to 
background average during confocal laser analysis, Mann-Whitney U-test was 
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performed. Mann-Whitney U-test was also used for dot blot analysis of total aquaporin 4 




Figure 3.  Example of confocal laser fluorescence intensity of a coronal section in rat 
brain.  For each coronal section, four regions of interest (ROI) (A) were selected and z-
stacks of images were acquired with an image spacing of 0.2 µm (B).  The image plane 
with the highest mean intensity was selected for measurements (B) to evaluate the 
localization of AQP4 immunoreactivity.  Four capillaries were analyzed in each selected 
z-plane (C).  Localization of AQP4 was quantified by calculating the ratio of the 
maximum intensity relative to the average intensity of pixels in the adjacent neuropil (D).  
Pixel intensity is measured in arbitrary units (AU) and sequential pixels along the line 
going through each capillary are expressed on the horizontal axis (D).  Each pixel 























Blood pressure, heart rate and core temperature 
 Each animal’s heart rate, temperature and blood pressure were recorded 
throughout anesthesia. Initial (t= 0 min), 15 min and final (t= 120 min) values are 
summarized in Tables 2 and 3.  Initial values were not significantly between treatment 
groups for any of these parameters (Heart Rate F=0.569, P=0.57; Core Temp F= 2.204 
P=0.13; Systolic Pressure F=0.233 P=0.79; Diastolic Pressure F= 2.28 P= 0.12).    
 A significant decrease in heart rate was observed in water-injected animals 15 min 
and two hours after water injection. A significant core body temperature decrease also 
was observed 15 min after water injection.  In water-treated animals a significant increase 
in systolic and diastolic pressure was observed at the 2 hour time point, but not 15 min 
after water injection. 
 Animals treated with desipramine had significantly elevated diastolic pressures at 
all time points compared to controls.  Diastolic pressures did not change during the two 
hour anesthesia within either the control or desipramine group.  At the two hour time 
point, these drug-treated animals also showed a decrease in core temperature compared to 




Table 2.  Heart rate and core temperature values are the mean ± SEM from 7-12 animals 
measured at initial (t = 0), 15 min (t = 15) and final (t = 120 min) time points.  For 
animals receiving IP water injection, 15 minute values are 15 min after the injection. * 




 Heart Rate  
Beats Per Minute ± SEM 
0 min           15 min       120 min 
Core Temperature °C ± SEM 
 
 0 min             15 min         120 min 
Control 392  ± 10 388 ± 9 379  ±  8 37.5 ± 0.2 37.6 ± 0.2 37.4 ± 0.2 
Water Injected 379 ± 8 334 ±13* 350 ± 9* 37.8 ± 0.2 35.6 ±0.2* 37. 6 ± 0.2 





Table 3.  Arterial systolic and diastolic pressure values are the mean ± SEM from 7-12 
animals measured at initial (t = 0), 15 min (t=15) and final (t = 120 min) time points. * 
indicates a significance difference compared to the initial values. ◊ indicates a 




 Arterial Systolic 
(mm Hg ± SEM) 
0 min          15 min      120 min 
Arterial Diastolic 
(mm Hg ± SEM) 
 0 min           15 min         120 min 
Control 103  ± 6 97 ± 6 91.4 ±  4 63 ± 4 60 ± 4 53 ± 5 
Water Injected 106 ± 7 110 ± 4 123 ± 7* 68 ± 4 75 ± 4 80 ± 5* 
Desipramine 107 ± 3 107 ± 4 103  ±  3 73 ± 3 
◊
 73 ± 3
◊







Blood plasma osmolality 
 Figure 4 shows blood plasma osmolality while animals were under anesthesia.  
Beginning osmolalities (measured at t = -20 min) were similar in each treatment group 
(F=0.340, p= 0.67).  The overall average osmolality of all animals was 295 ± 1 mOsm.  
Relative to the initial value, osmolality decreased significantly in the water injection 
group 15, 30, 60, 90 and 120 min after intraperitoneal injection (t = 0). Blood osmolality 
dropped drastically during the first thirty min after IP injection and appeared to stabilize 
to a constant value thereafter. Plasma osmolality of control and desipramine groups 




Figure 4.  Blood plasma osmolality of control and treatment groups during anesthesia.  
Time -20 min indicates the time immediately after femoral catheter insertion.  At time 
zero animals in the water injection group received an intraperitoneal water injection.  * 








Figure 5.  Blood was collected for hematocrit analysis immediately following femoral 
artery catheterization (initial) and at the termination of the experiment approximately two 
hours later (final).  Relative packed cell volume is shown on the Y axis.  Error bars 









 The hematocrit of arterial blood was measured in animals from all three groups 
immediately after the initial insertion of the arterial catheter and at the termination of the 
experiment (Figure 5).  ANOVA analysis of the initial hematocrit value between the three 
groups showed no significance (F=0.466, p=0.63).  The control group showed a 
significant decrease (8.4% ±1.8) in hematocrit during the experiment.  Water injected 
animals had a significant increase (11.0% ± 1.7) in packed cell volume.  The plasma in 
the water injected animals was also red in color for the final determination.  No 
difference was seen in the desipramine group.   
Cortical brain water content  
 Control animals had 79.8 ± 0.2 %water in cerebral cortical brain tissue (Table 4).  
The water-injected animals showed a significant increase in cortical brain water content, 
to 81.3 ± 0.1 % water.  No difference in brain water content (79.2 ± 0.4 %) was noted in 




Table 4.  Cortical brain tissue water content of the three rat groups.  Water content was 
determined by ((brain wet weight – brain dry weight) / (brain wet weight)) x 100%.  * 




Groups Brain Water Content 
% ± SE 
N 
Control          79.8  ± 0.2    4 
Water Injected          81.3  ± 0.5* 4 





Aquaporin 4 epifluorescence immunohistochemistry 
Coronal sections from the mid-frontal regions were used to investigate AQP4 
localization in the rat brain.  Strong signal intensities for AQP4 immunoreactivity were 
seen along endothelial cells throughout the cerebral cortex as indicated by colocalization 
of immunoreactivity for the blood brain barrier (SMI-71) and AQP4 markers (Figure 6).  
In capillaries AQP4 appeared to be superimposed on the SMI-71 antibody.  In larger 
vessels however, a clear distinction can be made between AQP4 and SMI-71 localization 
with AQP4 surrounding the blood vessels endothelial layer. In contrast, AQP4 
immunoreactivity was colocalized with glial fibrillary acid protein immunoreactivity near 
blood vessels (Figure 7.  Strong AQP4 staining also was observed at the glial limitans 
(Figure 7) and near the ependymal cells of the choroid plexus.   
Aquaporin 4 distribution at astrocyte endfeet 
Three rats were used in each group and 48-64 capillaries were measured per rat 
(Figure 8).  Relative to background staining, the intensity of AQP4 immunoreactivity 
increased significantly in both the water-injected and desipramine treated groups, when 
compared to the controls (Table 5).  Water injected animals show a 24% increase in 
AQP4 relative immunofluorescence compared to controls.  Desipramine treated animals 













Figure 7.  Epifluorescence of AQP4 immunoreactivity around a cerebral vessel (top left, 
and at glial limitans (bottom). GFAP immunoreactivity around cerebral vessel (top right).  







Table 5.  Peri-capillary aquaporin 4 signal strength recorded with quantitative confocal 
microscopy.  The signal intensity represents the ratio between the maximum intensity at a 
capillary wall relative to the background.  * indicates significant difference compared 




 Signal Intensity ± SE N 
Control 2.6 ± 0.04 3 
Water Injected 3.2 ± 0.21* 3 






Figure 8.  Aquaporin intensity profile through a cerebral vessel. The histogram 
corresponds to pixel intensity along the blue arrow seen on the confocal laser micrograph. 
The ratio of the maximal signal to the average of five pixels in the background was 
compared between each treatment group. AU indicates arbitrary units used to measure 





















Aquaporin 4 expression  
 Western blot analysis of brain lysate showed a single band when probed for to β-
actin (Figure 9A).  Immunoreactivity of AQP4 showed several bands between 25-75 kD, 
with intense staining at higher molecular weights.  Sample buffer containing 5% β-
mercaptoethanol (1x BME) was used for these initial investigations (Figure 9 A and B). 
In an attempt to increase AQP4 stain in a single distinct band at the expected molecular 
weight increased concentration of reducing agents were used.  Concentrations of BME 
equal to 2 or 4 times normal did not appreciably change appearance of the AQP4 western 
blot (Figure 9 A1-3). Replacing BME with 1M dithiothreitol (1x DTT) also resulted in a 
spread of high molecular weight with no distinct band at lower molecular weights.  
Increasing the concentration of either reducing agent caused higher molecular weight 
staining, and a decrease in banding at the expected value.  An 8 fold increase in BME 
(C3) eliminated almost all banding below ~100kDal and produced single high molecular 
weight band.  In addition to altering reducing agent concentration several other variables 
were altered in order to attempt to observe a band at the expected level.  Changes in the 
lysis buffers, heating techniques, transfer time, transfer voltage, antibody incubation 
length, and varying concentration of antibodies were performed.  A distinct band at the 




Figure 9.   Western blots probed for AQP4 and β-actin.  Membrane A corresponds to β-
actin immunoreactivity in 15 µg (Lane 1) and 30 µg (Lane 2) of brain lysate.  Membrane 
B and C correspond to AQP4 immunoreactivity in 15 µg (Lane B1) and 30 µg (Lane B2: 
C1-C7) of brain lysate.  Lysates probed in membrane C were treated with one of two 
reducing agents (DTT and β-mercaptoethanol (BME)) at various concentrations C1: 
355mM BME, C2: 750 mM BME, C3: 2840 mM BME, C4: 50 mM DTT, C5: 100mM 








Protein quantification using dot blot method 
An initial analysis was performed to determine the relation between AQP4 
immunoreactivity and quantitity of brain lysate added to dot blot wells.  Various 
quantities of brain lysate from a control animal was loaded into each well.  The resulting 
pixel intensity showed a linear increase with the total amount of control brain lysate 




Figure 10.  Control rat brain lysate probed for AQP4 using different amounts of control 
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Aquaporin 4 antibody binding specificity 
Preabsorbing the AQP4 primary antibody with an AQP4 control peptide produced 
a decrease in pixel intensity in two control brain lysate samples (10 µg and 40 µg) (Figure 
G).  Neonatal liver and bovine serum albumin served as a negative control and showed 
minimal intensity when probed for AQP4.  Aquaporin 4 control peptide and brain lysate 
were loaded as positive controls (Figure 11). 
Aquaporin 4 expression following water injection and desipramine treatment 
 Cerebral cortical aquaporin 4 content determined with dot blot analysis did not 
change significantly across the three treatment groups (F=0.403, P=0.68). There was a 
wide variability of the raw data within each treatment group: control (23.5 AU ± 8.7), 
water injected (29.2 AU ± 10.2) and desipramine (25.4 AU ± 6.5).  Similar coefficients of 
variability also were seen within each group when β-actin immunoreactivity was 
analyzed: control (5.6 AU ± 0.40), water injected (8.0 AU ± 1.6) and desipramine (5.2 ± 
1.2).  However, β-actin immunoreactivity showed a significant increase in the water 
treatment group compared to controls.  The ratio of AQP4 immunoreactivity relative to β-
actin immunoreactivity showed no significance across the three animal groups (F=0.787, 
P=0.49).  However, normalizing AQP4 immunoreactivity data to β-actin decreased the 
coefficient of variation compared to un-normalized AQP4 immunoreactivity. Normalized 




Figure 11.  Specificity of aquaporin 4 antibody dot blot analysis.  Preabsorption of 
primary antibody with a 17 amino acid c-terminus AQP4 control peptide (A).  Two 
protein amounts were loaded on a vacuum dot blot aparatus.  The intensity of each well 
probed with native or preabsorbed antibody is shown in B. Liver, bovine albumin, brain 








Table 6.  Aquaporin 4 immunoreactivity normalized to β-actin using dot blot analysis 











Control 4.25 0.85 4 
Water 
Injected 3.77 0.90 3 




















Aquaporin 4 localization and expression response to osmotic brain edema 
A successful induction of osmotic brain edema was confirmed by changes in 
serum osmolality and brain water content.  While water injection also caused a significant 
decrease of the core temperature after fifteen min the animals recovered to normal body 
temperature within two hours.  Consistent with previous studies [44, 47, 69, 70, 107], 
blood plasma osmolality showed a significant drop  from 294 ± 2.5 mOsm to 277 ± 1.3 
mOsm 15 min after the intraperitoneal water injection.  After the initial drop observed at t 
= 15 min, blood osmolality remained relatively stable throughout the remaining two hour 
study.   A significant increase in hematocrit of water injected animals also provides 
evidence for systemic hypotonicity. As absorption of water into the mesenteric 
vasculature reduces the tonicity of the plasma, an osmotic gradient would move water 
into the erythrocytes.  The increase observed in the packed cell volume is evidence of this 
swelling.  Additionally, after water intoxication the plasma fraction contained some red 
color, evidence of erythrolysis.    Interestingly, the control animals showed a slight, but 
significant, decrease in a hematocrit.  This decrease is probably a result of repetitive 
blood sampling with liquid replacement.  After each blood extraction an equal amount of 
normalized saline was injected into the animal to maintain patency of the arterial line.  
This may have reduced the number of circulating blood cells and diluted those which 
remain.   
Consistent with several other publications regarding osmotic brain edema [46, 60, 
69, 70, 81], brain water content showed a significant increase in water-injected animals.  
It is suspected that systemic hyposmolarity caused an efflux of water from the lumen of 
the capillaries into the brain interstitial space. To determine the role AQP4 plays during 
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influx of water into the brain parenchyma, immunohistochemistry was performed on 
control and water-treated rats.  In both groups we observed strong AQP4 localization at 
astrocytic endfeet surrounding capillaries.  This AQP4 immunoreactivity at the astrocytic 
endfeet was increased in water-treated animals.  Similar findings of increased AQP4 
immunoreactivity during 1.5 and 4 hours of osmotic brain edema have been reported 
elsewhere [44, 46].   
Analysis of AQP4 expression using western blot analysis proved ineffective.  We 
observed immunoreactivity to the AQP4 antibody at high molecular weights together 
with one band near the reported AQP4 molecular weight of 34 kDa (Figure 9B).  Similar 
outcomes were observed using a variety of cell lysis kits (MCL-1 Sigma Aldrich; 
FractionPREP, Biovision) containing various detergents, reducing agents, and 
concentrations of primary and secondary antibodies.  We suggest that the higher weight 
immunostaining is a result of AQP4 oligomers that do not separate in the lysis process 
nor dissociate during electrophoresis.  The inability to quantify the results using western 
blot analysis prompted a different approach. A 1D dot blot method was used.  We 
demonstrated that dot blot analysis can be used to quantitatively measure AQP4 content 
by; 1) showing an increase of immunoreactivity with an increase of total protein (Figure 
10), 2) showing negative AQP4 immunoreactivity for bovine serum albumin and neonatal 
liver, and 3) showing a decrease in AQP4 immunoreactivity when probed with AQP4 
antibody that had been preabsorbed with AQP4 antigen peptide (Figure 11).  Unlike 
previous findings [44] we did not observe any differences in AQP4 expression during 
osmotic brain edema.  There could be several explanations for this different result.  First, 
in one previous study Vajda et al. [44] measured AQP4 expression at 4 and 48 hours, 
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while we measured at two hours, a time where BBB water permeability has decreased 
[44, 70]. Secondly previous studies analyzed only bands near the reported weight, while 
we measured all AQP4 immunoreactivity using dot blot analysis. Interestingly, others 
reported that AQP4 mRNA expression also is unaltered during 4 and 48 hour osmotic 
brain edema [44].   
The increase in AQP4 localization at astroglial endfeet using 
immunohistochemistry but no increase in total AQP4 expression using dot blot analysis 
suggests that either; 1) there was an increase in availability AQP4 polarized to the endfeet 
by protein redistribution or 2) A conformational change at the c-terminus of AQP4 during 
osmotic brain edema results in a higher affinity of antibody to epitope.  In summary the 
analysis of AQP4 suggests that the increase in AQP4 immunoreactivity at the astrocytic 
endfeet is not a result of increased total AQP4 protein in the brain but possibly 
redistribution of AQP4 along the astrocytic membrane.  Thus any AQP4 alterations in 
response to systemic hyponatremia are a result of post transcriptional factors.   
Aquaporin 4 localization and expression response following chronic treatment of 
desipramine 
Our goal in the second part of the project is to determine if a tricyclic 
antidepressant (TCA), which has been shown to increase BBB water permeability in the 
brain [106, 113], would alter AQP4 expression and distribution.  Modification of brain 
catecholamines has been shown to affect BBB transport of water [13, 14]. Desipramine 
was chosen from other TCAs because of its selective effect on the noradrenergic system. 
Desipramine and other secondary amine TCAs show a higher potency to inhibit 
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norepinephrine reuptake compared to tertiary amine TCAs [115, 116].  In addition, a 
previous study using quantitative autoradiography shows desipramine’s high binding 
affinity to norepinephrine terminals [117].  
Animals receiving daily treatments of desipramine for 14 days had similar heart 
rates, systolic blood pressures and core temperatures compared with untreated controls.  
However diastolic blood pressure was elevated significantly compared to controls.  This 
elevation in diastolic blood pressure is also observed in humans undergoing TCA 
treatment [118].  Blood osmolality and hematocrit of desipramine-treated animals 
showed no significant difference compared to controls.  The general location of AQP4 
immunostaining also was unchanged between the two groups, showing strong staining at 
both astrocytic endfeet and at the glial limitans.  Quantitative analysis of AQP4 
immunostaining intensity at astroglial endfeet however, showed a significant elevation in 
the desipramine group compared to controls.  The increase in AQP4 immunostaining at 
the endfeet was not reflected in AQP4 findings using dot blot analysis.  Thus, our 
findings suggest that the AQP4 signal increase at the astroglial endfeet is not a result of 
an increase in global protein expression but instead a possible redistribution along the 
astrocytic membrane.  Increased immunostaining at the endfeet however could also be a 
result of a change in AQP4 c-terminus conformation during treatment.  The findings that 
AQP4 redistribution occurs toward the glial endfeet is consistent with the increase in 
water permeability in the brain seen after desipramine treatment [113].  To our 
knowledge this is the first study showing evidence of an increase in AQP4 
immunostaining at astrocytic endfeet during chronic TCA treatment.  Since desipramine 
selectively inhibits norepinephrine reuptake [119], we suggest that the noradrenergic 
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system either directly or indirectly regulates AQP4 distribution.  This connection of the 
noradrenergic system regulating AQP4 expression has been suggested elsewhere [120].  
It has been shown previously that stimulation of the locus coeruleus in the monkey 
increases water permeability in the brain [13], but it is unclear if this increase in water 
permeability is from a distribution of AQP4 or stimulation of AQP4 activity.   
In conclusion we have examined AQP4 distribution and expression using two 
models, which have been shown to alter water permeability in the brain. Interestingly, 
each of these models show opposite effects in cerebral water permeability.  We suggest 
that the increase of AQP4 immunostaining in desipramine-treated animals is a reflection 
of an increase of AQP4 at the astrocytic endfeet from redistribution and not from an 
increase of total AQP4 protein expression in the brain.  In contrast, the down regulation 
of water permeability in water-injected animals observed previously is not due to a 
redistribution of AQP4 away from the astrocytic endfeet.  Instead alterations in AQP4 
activity must play an important role in regulating water permeability in this model of 
cytotoxic brain edema.   
Limitations and future directions 
Our study has several limitations.  Our immunohistological studies were 
structured to evaluate AQP4 staining in the cerebral cortex.  Cerebral cortex was selected 
because it has been shown to have a higher density of capillaries compared to white 
matter [121]. Our results showing an increase in AQP4 signaling at the astrocytic endfeet 
should not be used to address the global distribution of AQP4 in the brain.  Additionally, 
our primary antibody was selective to the c-terminus of AQP4.  Changes in c-terminus 
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configuration making the epitope more accessible to the antibody is a potential cause for 
the observed increase in AQP4 immunoreactivity at astroglial endfeet.  Additional 
antibodies directed to the n-terminus or another location should be used to confirm these 
results.  However, care should be taken when choosing n-terminus antibodies because of 
differences between the three isoforms of AQP4 are at the n-terminus.  In order to firmly 
establish the possible redistribution of AQP4 during these treatments, freeze fracturing 
technique may be used.   
Western blot analysis was show to be ineffective using our methodology.  Most 
publications do not show entire blots of AQP4 probed membranes to determine if 
multiple oligomers are present.  Several sources have suggested dimers and tetramers of 
AQP4 are present in westerns blots; however, few have measured these.  Measuring all 
bands to determine total AQP4 protein expression may be the best method to determine 
AQP4 protein content in the brain.  Our results showed a large coefficient of variation 
using 3-5 animals per group.  An increase in power may decrease this variability.  
Aquaporin 4 regulation mechanisms and their role in water transport in the brain are still 
largely understudied.  Additional studies regarding protein expression, localization, and 
structural modification of AQP4 should be performed in order to determine this 
mechanism regulating blood-brain barrier water permeability and devise therapeutic 
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